Auszug
Die Statine haben ihre dominierende Stellung weiter ausgebaut und erreichten 2005 92% der Verordnungen bei den lipidsenkenden Arzneimitteln. Diese Entwicklung beruht auf ihrer hervorragenden Wirkung in der Prävention der koronaren Herzkrankheit. Fibrate sind weiter rückläufig, da nur mit Gemfibrozil signifikante Effekte auf kardiale Endpunkte in Langzeitstudien beschrieben wurden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (1999): Empfehlungen zur Therapie von Fettstoffwechselstörungen. Arzneiverordnung in der Praxis, Sonderheft 1. Internet: www. akdae.de/35/95_Fettstoffwechsel_1999_ 2Auflage.pdf.
Arzneimittelkommission der deutschen Ärzteschaft (2004): Myopathien bzw. Leberreaktionen unter Ezetimib (Ezetrol®) (Aus der UAW-Datenbank). www. akdae.de/2020/20040402. html.
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ et al. for the Ezetimibe Study Group (2003): Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 107: 2409–2415.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy — Thrombolysis in Myocardial Infarction 22 Investigators (2004): Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504.
Cholesterol Treatment Trialists’ (CTT) Collaborators (2005): Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.
Coronary Drug Project (1975): Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381.
Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP et al. (2002): Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40: 2125–2134.
De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R et al. (2003): European Guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart Journal 24: 1601–1610.
De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD et al.; A to Z Investigators (2004): Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292: 1307–1316.
De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N (1999): Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 99: 779–785.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998): Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622.
Fux R, Möricke K, Gundel UF, Hartmann R, Gleiter CH (2004): Ezetimibe and statinassociated myopathy. Ann. Intern. Med. 140: 671–672.
Gagné C., Gaudet D., Bruckert E. for the Ezetimibe Study Group (2002): Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105:2469–2475.
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association (2004): Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227–239.
Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group (2002): Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162: 1568–1576.
Heart Protection Study Collaborative Group (2002): MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.
Helsinki Heart Study (1987): Primary-prevention trial with gemfibrozil in middleaged men with dyslipidemia. N Engl J Med 317: 1237–1245.
Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML et al (2006): Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295: 655–666.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2005): Nutzenbewertung der Statine unter besonderer Berücksichtigung von Atorvastatin. Internet: www.iqwig.de/publikationen-des-iqwig.114.html
Jenkins DJA, Kendall CWC, Marchie A, Faulkner DA, Wong JMW et al. (2003): Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290: 502–510.
Knopp RH, Gitter H, Truitt T, Bays H, Manion CV et al. Ezetimibe Study Group (2003): Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24: 729–741.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators (2005): Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435.
Law MR, Wald NJ, Rudnicka AR (2003): Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit Med J 326: 1423–1430.
Lipid Research Clinics Program (1984): Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 351–364, 365–374.
McKenney JM (2005): Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 96: 60E–66E.
Melani L, Mills R, Hassman D, Lipetz R, Lipka L. et al. Ezetimibe Study Group (2003): Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 24: 717–782.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421.
National Institute for Health and Clinical Excellence (2006): Statins for the prevention of cardiovascular events. Technology Appraisal 94. Internet: www.nice.org.uk/TA094
Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators (2005): Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29–38.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group (2005): High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: 2437–2445.
Pyörälä K, Pedersen RT, Kjekshus J, Faergeman O, Olsson AG et al. (1997): Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20: 614–620.
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators (2005): C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28.
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group (1999): Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341: 410–418.
Sacks FM (2002): Low-density lipoprotein lowering therapy: An analysis of the options. J. Am. Coll. Cardiol. 40: 2135–2138.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD et al. (1996): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009.
Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.
Schönbeck U, Libby P (2004): Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109(Suppl II): II 18–26.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001): Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718.
Sever SP, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. (2003): Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 361: 1149–1158.
Shepherd J, Blaun GJ, Murphy MB et al. (2002): Pravastatin in elderly individuals at risk of vascular disease (PROSPER), a randomised controlled trial. Lancet 360: 1623–1630.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR et al. for the West of Scotland Coronary Prevention Study Group (1995): Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307.
Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA (2004): Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512–3517.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288: 2998–3007.
The Bezafibrate Infaction prevention (BIP) Study Group (2000): Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infaction Prevention (BIP) study. Circulation 102: 21–27.
The Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group (1998): Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349–1357.
Wiesner G, Grimm J, Bittner E (1999): Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61 (Sonderheft 2): S72–S78.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Klose, G., Schwabe, U. (2007). Lipidsenkende Mittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_34
Download citation
DOI: https://doi.org/10.1007/978-3-540-34370-7_34
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-34369-1
Online ISBN: 978-3-540-34370-7
eBook Packages: Medicine (German Language)